Market Cap: $16.07B
NI
Neurocrine Biosciences, Inc.
NBIX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $16.07B
Neurocrine Biosciences (Ticker: NBIX) is making headlines with its groundbreaking findings from the CRENESSITY trial, presented at the ENDO 2026 conference. This trial marks a significant milestone, r…
Neurocrine Biosciences (Ticker: NBIX) is making headlines with the unveiling of new CRENESSITY data at the ENDO 2026 conference, which could have significant implications for the management of congeni…
Neurocrine Biosciences, Inc. (Ticker: NBIX) makes significant strides in treating congenital adrenal hyperplasia (CAH) with its investigational drug CRENESSITY (crinecerfont). Recent data from the Pha…
Neurocrine Biosciences (Ticker: NBIX) secures its role as a leading innovator in endocrinology with the recent unveiling of significant findings from its CAHtalyst® Adult study for the treatment of cl…
Neurocrine Biosciences (Ticker: NBIX) highlights crucial advancements in the treatment of tardive dyskinesia (TD) with the recent findings from its KINECT® 4 clinical trial. The study reveals that a r…
Neurocrine Biosciences (Ticker: NBIX) is set to showcase important long-term data on its treatment for congenital adrenal hyperplasia (CAH) at the upcoming ENDO 2026 conference. As the company prepare…
Neurocrine Biosciences has reached a definitive agreement to acquire Soleno Therapeutics for $53.00 per share, totaling an equity value of $2.9 billion. This strategic acquisition aims to enhance Neur…
New Guidelines Aim to Improve Management of Tardive Dyskinesia in Long-term Care Settings Neurocrine Biosciences, Inc. unveils a pivotal initiative at the PALTmed PALTC26 Annual Conference, offering a…
Neurocrine Biosciences Participates in Stifel 2026 Virtual CNS Forum to Highlight Commitment to Neurological Health Neurocrine Biosciences, Inc. engages in a forward-looking dialogue about advancement…
Neurocrine Biosciences: Leading Innovation in Neurological and Endocrine Therapeutics Neurocrine Biosciences, Inc., a key player in the biopharmaceutical landscape, is profoundly focused on addressing…
Neurocrine Biosciences Takes Center Stage at Stifel CNS Forum Neurocrine Biosciences, Inc., a leading biopharmaceutical company, announces its participation in the upcoming Stifel 2026 Virtual CNS For…
Neurocrine Biosciences Highlights Superior VMAT2 Target Engagement of INGREZZA® at Recent Conference Neurocrine Biosciences, Inc. presents compelling findings on its drug INGREZZA® (valbenazine) durin…
Neurocrine Biosciences Presents Groundbreaking VMAT2 Target Occupancy Findings Neurocrine Biosciences, Inc. unveils compelling data from a recent study at the American College of Neuropsychopharmacolo…
Neurocrine Biosciences: Pioneering Innovative Treatments for Complex Disorders Neurocrine Biosciences, Inc. stands out as a leading biopharmaceutical company focused on advancing treatments for neurol…
Neurocrine Biosciences: Pioneering Treatments for Neuroendocrine Disorders Neurocrine Biosciences, Inc. stands out in the biopharmaceutical landscape with its commitment to developing innovative treat…
Neurocrine Biosciences Accelerates Innovation in Neurology and Beyond Neurocrine Biosciences, Inc. is at the forefront of a transformative phase in its research and development strategy, as it aims to…
Neurocrine Biosciences Advances R&D Strategy with Focus on Neurological and Metabolic Disorders Neurocrine Biosciences, Inc. is embarking on an ambitious new phase in its research and development stra…
Neurocrine Biosciences Charts Ambitious R&D Pathway Neurocrine Biosciences, Inc. embarks on an ambitious new direction in its research and development strategy, underscoring its commitment to deliveri…
Neurocrine Biosciences Prepares for 2025 R&D Day to Showcase Neuroscience Advances Neurocrine Biosciences, Inc. is set to host its 2025 Research and Development Day on December 16, 2025, at 12:00 p.m.…
Neurocrine Biosciences Set to Showcase R&D Innovations at 2025 Event Neurocrine Biosciences, Inc. announces its 2025 Research and Development (R&D) Day, scheduled for December 16, 2025, at 12:00 p.m.…
Neurocrine Biosciences to Showcase R&D Advancements in Upcoming Event Neurocrine Biosciences, Inc. is gearing up for its 2025 Research and Development (R&D) Day, set to take place on December 16, 2025…
Neurocrine Biosciences Enhances Understanding of Tardive Dyskinesia Treatment with New Review Publication Neurocrine Biosciences, Inc. has made a significant contribution to the treatment landscape of…
Neurocrine Biosciences Advances Understanding of Tardive Dyskinesia Treatment with New Clinical Review Neurocrine Biosciences, Inc. recently publishes a peer-reviewed narrative review in CNS Spectrums…
Innovative Approaches in Drug Development: Roivant Sciences' Strategic Direction Roivant Sciences is making significant strides in the pharmaceutical industry through its innovative approach to drug d…
Innovative Drug Development: Roivant Sciences' Strategic Positioning in the Biopharmaceutical Landscape Roivant Sciences is at the forefront of transformative drug development, leveraging cutting-edge…
Neurocrine Biosciences Embraces AI Innovations in Neurological Research Neurocrine Biosciences is at the forefront of incorporating artificial intelligence (AI) into its neurological research initiati…
Neurocrine Biosciences Gears Up for Earnings Announcement Amidst Strategic Growth Neurocrine Biosciences is poised to announce its quarterly earnings on October 28, 2025, with significant interest fro…
Neurocrine Biosciences: Advancing Neurological Treatment Innovations Neurocrine Biosciences is poised to reveal its quarterly earnings on October 28, 2025, and expectations are set high among industry…
Neurocrine Biosciences: Navigating a Complex Biopharmaceutical Landscape Neurocrine Biosciences is currently at a pivotal juncture in the biopharmaceutical sector, as evidenced by the diverse range of…
Neurocrine Biosciences: Navigating a Complex Biopharmaceutical Landscape Neurocrine Biosciences, a key player in the biopharmaceutical industry, faces a challenging yet promising landscape as it seeks…
Analysts Weigh In on Neurocrine Biosciences: A Diverse Outlook Amid Competitive Pressures In the past quarter, Neurocrine Biosciences (NASDAQ: NBIX) garners attention from analysts, who present a rang…
Neurocrine Biosciences Advances Huntington's Disease Treatment with INGREZZA® Findings Neurocrine Biosciences, Inc. presents compelling new data from the KINECT®-HD2 study, showcasing the effectivenes…
New Developments in Huntington's Disease Management: Neurocrine Biosciences’ INGREZZA® Shows Promise Neurocrine Biosciences, Inc. has recently showcased significant advancements in the treatment of Hu…
Neurocrine Biosciences Advances in Neurological Treatment with Innovative Drug Development Neurocrine Biosciences is making significant strides in the treatment of neurological disorders through its f…
Neurocrine Biosciences Reveals Promising Results for INGREZZA® in Treating Tardive Dyskinesia Neurocrine Biosciences, Inc. announces significant findings from a post-hoc analysis of its Phase 4 KINECT…
Neurocrine Biosciences Advances Tardive Dyskinesia Treatment with INGREZZA® Findings Neurocrine Biosciences, Inc. has recently unveiled compelling results from a post-hoc analysis of its Phase 4 KINEC…
Neurocrine Biosciences Advances Treatment for Tardive Dyskinesia with New Findings Neurocrine Biosciences, Inc. announces pivotal findings from a post-hoc analysis of its Phase 4 KINECT-PRO™ study, sh…
Neurocrine Biosciences: Navigating Analyst Perspectives on Growth Potential Neurocrine Biosciences (NBIX) finds itself under the spotlight as a dozen analysts provide a diverse array of ratings, indic…
Neurocrine Biosciences: Navigating a Complex Biotech Landscape Neurocrine Biosciences (NBIX) stands at a pivotal moment in the biotechnology sector, marked by a flurry of recent analyst ratings that r…
Neurocrine Biosciences Engages Stakeholders Through Upcoming Investor Conferences Neurocrine Biosciences, Inc. actively participates in the healthcare dialogue by announcing its involvement in four in…
Neurocrine Biosciences Showcases Commitment to Neuroscience at Upcoming Conferences Neurocrine Biosciences, Inc., a leader in the biopharmaceutical industry focusing on neurological and neuropsychiatr…
Neurocrine Biosciences Engages Investors with Upcoming Conference Presentations Neurocrine Biosciences, Inc. (Nasdaq: NBIX) actively prepares for an array of investor conferences scheduled for Septemb…
Neurocrine Biosciences: Innovations in Neurological Therapeutics Neurocrine Biosciences is at the forefront of developing innovative treatments for neurological disorders, with a particular focus on c…
Neurocrine Biosciences Eyes Growth Amid Competitive Biopharmaceutical Landscape Neurocrine Biosciences, a prominent player in the biopharmaceutical industry, continues to navigate a dynamic market cha…
Neurocrine Biosciences: Fostering Innovation in Neurological Treatment Neurocrine Biosciences continues to make significant strides in the field of neurological therapies, with a focus on developing a…
Neurocrine Biosciences Faces Divergent Analyst Sentiments Amidst Innovative Drug Development Neurocrine Biosciences (NBIX) currently finds itself at the center of a complex analysis conducted by 14 fi…
Neurocrine Biosciences: Navigating a Complex Landscape in Neurological Therapies Neurocrine Biosciences (NBIX) stands at a pivotal juncture as it garners attention from 14 analysts who evaluate its po…
Assessing Neurocrine Biosciences: A Snapshot of Analyst Perspectives Neurocrine Biosciences (NBIX) finds itself at the center of a nuanced analysis conducted by 14 analysts, each offering varied insig…
Analyst Perspectives Illuminate Neurocrine Biosciences' Market Position Neurocrine Biosciences (NBIX) stands at a critical juncture, as recent reports reveal a diverse array of ratings from 16 analyst…
Analyst Perspectives Shape Neurocrine Biosciences’ Market Outlook In the biopharmaceutical sector, the insights provided by analysts play a pivotal role in shaping perceptions of a company's future. R…